This policy describes and clarifies coverage for Lab-Developed Tests (LDTs),
Federal Drug Administration (FDA)-cleared, and FDA-approved clinical
laboratory tests in hereditary cancer tests including Next-Generation
Sequencing (NGS) tests as allowable under the National Coverage Determination
(NCD) 90.2, under section D describing Medicare Administrative Contractor
(MAC) discretion for coverage. This policy's scope is specific for hereditary
germline testing, and is exclusive of polygenic risk scores, solid tumor,
hematologic malignancies, circulating tumor deoxyribonucleic acid (DNA)
testing (ctDNA), and other acquired cancer-related tests.

**Criteria for Coverage**  
All the following must be present for coverage eligibility:

  * The patient must have: 
    * Any cancer diagnosis
    * AND a clinical indication for germline (inherited) testing for hereditary cancer
    * AND a risk factor for germline (inherited) cancer
    * AND has not been previously tested for the same germline genetic content.
  * The test has satisfactorily completed a Technical Assessment (TA) by Molecular Diagnostic Services Program (MolDX) for the stated indications of the test.
  * The test performed includes **at least** the minimum genetic content (genes or genetic variants) with definitive or well-established guidelines-based evidence required for clinical decision making for its intended use that can be reasonably detected by the test. 
    * Because these genes and variants will change as the literature and drug indications evolve, they are listed separately in associated documents, such as the MolDX TA forms.
    * A single gene or variant may be tested if it is the only gene or variant considered to be reasonable and necessary for a cancer type.
  * If a previous test was performed with a similar/duplicative intended use, a subsequent test is only reasonable and necessary if the non-duplicative genetic content of the second test is reasonable and necessary.
  * If the test is an NGS test, it must abide by all conditions listed in the NCD 90.2.

**Situations in which a test should not be used or coverage is denied:**  
The test in question will be non-covered if:

  * It is an NGS test and does not fulfill all the criteria set forth in the NCD 90.2
  * A previous test was performed for the same genetic content
  * It is a panel or single gene test used to identify a known familial variant(s) that could be identified with a test targeted to that specific variant(s)
  * It is a panel or single gene test used to confirm a variant(s) detected by somatic tumor testing that can be confirmed by a test targeted to that specific variant(s)
  * A satisfactory TA is not completed
  * For tests that are currently covered but a TA submission has not been made, providers must submit complete TA materials by the original effective date of the policy or coverage will be denied.

An estimated 5-10% of cancers have a heritable component, and there are a
growing number of hereditary cancer syndromes.1-5 Identifying pathogenic
variants in genes associated with hereditary cancer syndromes can uncover
genomic mechanisms that have predictive, diagnostic, and prognostic utility to
patients and are used to better their management.6-8 Pathogenic variants in
germline genes have been associated with an increased lifetime risk of
hereditary breast and ovarian cancer (HBOC), colorectal cancer (CRC), as well
as other cancers, such as endometrial, pancreatic, prostate, and melanoma.
Traditionally, testing of genes associated with hereditary cancers was
performed based on specific gene-disease relationships and an individual's
personal or family history, often in a single-gene reflex fashion. However,
the growing number of genes known to be associated with hereditary cancer
syndromes and the overlap between clinical presentations has challenged this
paradigm.

The application of NGS technology has facilitated multi-gene panel testing for
definitive genes associated with many hereditary cancer syndromes. NGS has
been shown to be more efficient than single-gene sequential testing, and is
becoming a routine component of the diagnostic process.1,9-11 For example,
_BRCA1_ and _BRCA2 (BRCA1/2)_ have historically been the most frequently
tested genes in HBOC. Yet, it is now estimated that more than half of the
individuals with hereditary breast cancer carry pathogenic variants in genes
other than _BRCA1/2_.10,12-14 Breast cancer is also a component of several
other hereditary cancer syndromes, such as Li-Fraumeni syndrome, Cowden
syndrome, hereditary diffuse gastric cancer and Peutz-Jeghers syndrome.15-19
Studies estimate that approximately 30% of all CRC cases are an inherited form
of disease20-22 and nearly 5% are associated with highly penetrant hereditary
clinical presentations. Lynch syndrome (LS), previously known as hereditary
non-polyposis colorectal cancer (HNPCC), is the most common hereditary CRC
syndrome accounting for 2-3% of all CRC. It is caused by germline pathogenic
variants in 5 mismatch repair genes, _MHL1, MSH2, MSH6, EPCAM_ and _PMS2_.
Traditionally, a testing cascade of microsatellite instability (MSI) analysis
and/or immunohistochemistry was performed followed by testing of individual
single genes. However, NGS allows for a majority of the genes to be tested
simultaneously, reducing the time to diagnosis and reducing costs.11,23 The
National Comprehensive Cancer Network (NCCN) guidelines have also expanded to
incorporate testing of multiple genes into medical management
recommendations.5,24-26 The established Centers for Medicare and Medicaid
Services (CMS) NCD 90.2 confirms testing using NGS to be both reasonable and
necessary in Medicare beneficiaries.

**Clinical Indications and Risk Factors**  
Although inherited cancer syndromes each have their own clinical criteria for
testing, there are some findings that are associated more frequently with
hereditary cancers when compared to those that are acquired including:
diagnosis at an earlier age than what is typically seen for that cancer type,
2 or more affected close blood relatives (first-, second- and third-degree
relatives) on the same side of the family with the same type of cancer,
multiple affected generations within 1 family. Additional findings include
multiple cancer types occurring in the same individual, cancers that develop
bilaterally, and presence of congenital conditions known to be associated with
a particular cancer syndrome.3,27



Additional factors are specific to certain cancer types. For example, factors
that significantly predict for a germline _BRCA1/2_ pathogenic variant in
breast cancer include Ashkenazi Jewish heritage, triple-negative breast
cancer, tumor histologic grade 3, and diagnosis prior to the age of 50.12
Multi-gene testing should also be considered in individuals with CRC with
adenomatous polyposis, colonic polyposis with an unknown histology, or when
more than 1 syndrome may explain the presentation. For example, 10 or more
adenomas are more likely to be associated with pathogenic mutations in genes
that cause classical familial adenomatous polyposis (FAP) or attenuated FAP or
MUTYH-associated polyposis (MAP). Whereas 2 or more hamartomatous polyps are
indicative of Peutz-Jeghers, Juvenile polyposis, and Cowden/PTEN hamartoma
syndromes.5 The risk of melanoma is influenced by sensitivity to Ultraviolet
(UV) radiation, sunburns during childhood, and sunlight exposure.28,29 The
NCCN has defined criteria for which testing of well-established germline genes
is appropriate for a variety of inherited cancers.5,24-26



**Test Description**  
NGS is currently the most common methodology utilized for hereditary cancer
gene testing. NGS is not a specific test, but a sequencing methodology
utilized to capture genomic information. Unlike Sanger sequencing (the prior
standard technology) that typically provides sequence information for a single
DNA strand/molecule, NGS allows for massively parallel sequencing of millions
of DNA molecules concurrently.30,31 This allows for capturing many relevant
genomic targets simultaneously, usually by utilizing technologies, such as by
polymerase chain reaction (PCR) amplification or hybrid capture. As such, NGS
tests for use in germline cancer are often comprised of gene panels whose
content is either relevant to a specific cancer type or condition, or a larger
panel of genes that can be used for multiple cancer types.

NGS tests can vary significantly for many reasons. While NGS defines a broad
methodology for massively parallel sequencing, different technologies that
have different strengths, weaknesses, and technical limitations or liabilities
are available.32 The most common sequencing platforms in clinical use today
sequence by synthesis similar to Sanger sequencing; these platforms utilize
different chemistries, signal amplification, and detection methods. Gene
panels can include only the portions of genes that contain the most critical
clinically relevant information, or be comprehensive, containing entire exonic
gene regions (coding regions), introns (non-coding regions), and even sequence
ribonucleic acid (RNA) for detecting abnormal transcripts. Downstream from the
pre-analytic processes mentioned above, the bioinformatics used to process and
assess the resultant sequencing reads and identify variants/mutations can
yield different results based on the software used and what types of variants
the test is attempting to detect. These software tools must take the resultant
sequencing file (generally starting with the FASTQ format), align all possible
sequences with a reference genome (BAM/SAM), and identify variants from the
reference (typically a VCF file). Once such variants are identified, they must
be assessed for validity and subsequently, for their clinical relevance.

The types of genomic information reported can vary, as tests can uncover a
myriad of genomic alterations, such as single nucleotide variants (SNVs),
Insertions/Deletions (INDELs), Copy Number Alterations ([CNAs]; these can be
simply amplifications at a single locus or chromosomal gains and losses),
Structural Alterations ([SAs]; inversions, insertions, translocations) and
abnormal RNA splice site variants. All these variant classes have demonstrated
clinical utility in germline testing. Additionally, NGS testing is highly
complex and requires expertise from handling the specimen, running the complex
equipment, understanding the required bioinformatics, interpreting the
findings and creating an actionable medical report. Guidelines for validating
clinical NGS panel tests and bioinformatics pipelines have been
published.33-35 Variant interpretation is also a crucial component of NGS
testing in hereditary cancers. The American College of Medical Genetics (ACMG)
and the Association for Molecular Pathology (AMP) have published standards and
guidelines for both sequencing and copy number variant interpretation that
have been widely adopted by clinical laboratories around the world.36-38



Multi-gene hereditary cancer panels offered by diagnostic clinical
laboratories vary on the number of genes that are included. The Clinical
Genome Resource (ClinGen) has developed a clinical validity framework that
evaluates evidence in the literature and determines the strength of
association of genes with disease using a point-based system. Genes that have
been repeatedly demonstrated in both the research and clinical diagnostic
settings to be associated with a particular disorder with no contradicting
evidence are considered definitive.39 Lee, et al., and Seifert, et al.,
describe the assessment of genes frequency tested in hereditary breast and
ovarian, and colorectal cancer and polyposis multi-gene panels, respectively,
using the ClinGen Gene Curation framework.40,41 These assessments considered
multiple lines of evidence including case reports, familial and case-control
association studies, and segregation data and describe genes that are
considered definitive for these cancer types.

Given the abundant literature on genetic and genomic testing in hereditary
cancer diagnosis and care, this contractor feels strongly that testing for
inherited cancer syndromes is appropriate for use in Medicare beneficiaries.
However, given the variability for what information tests can provide,
additional information must be submitted by providers to ensure the contractor
A) understands what test is being performed; B) Why it is being performed; C)
If the test is both reasonable and necessary for cancer care for its intended
use.

Based on the evidence, guidance, and current best practices, a multi-gene
panel must contain more than 1 single gene on that panel necessary for proper
patient care to be considered reasonable and necessary for the indicated
cancer type. Additionally, a gene panel must contain, at a minimum, all the
necessary relevant gene content required for their indicated use to meet
clinical utility requirements. Such minimum criteria are determined by experts
including the NCCN, ASCO, ACMG and the AMP, and are considered during the TA.
A multi-gene panel is not considered reasonable and necessary, if only a
single gene on the panel is considered reasonable and necessary. In some
cases, a single gene may be tested, if it is the only gene considered to be
reasonable and necessary for a cancer type. For example, the only gene
associated with multiple endocrine neoplasia type 1 is _MEN1_.26,42,43
However, testing for additional genes for that encounter will, therefore, not
be considered reasonable and necessary.

**Analytical Validity and Clinical Utility**

Because of the number of variables described above, additional work must be
performed to assess if any given test is both reasonable and necessary for
Medicare beneficiaries and to ensure that Medicare claims are properly
understood and executed. MolDX has instituted a process for completing a TA
that ensures that tests are appropriate for their indications and are properly
validated according to published guidelines described above (when applicable).
Specifically, in order to understand if a test is both reasonable and
necessary, it must be delineated if a test has the properly validated
technology, variant types, gene and variant coverage, and bioinformatics
capability to deliver a clinically useful result for the Medicare beneficiary,
given their diagnosis.

Labs seeking coverage for LDTs, FDA-cleared, or FDA-approved tests that are
not nationally covered must submit documentation to allow MolDX to complete a
TA. Forms to complete the process are available on the MolDX website. Tests
that are currently covered by Palmetto GBA are not exempt from this process.
Tests that are currently covered and have not undergone a TA by MolDX will be
non-covered unless complete documents to perform a TA are submitted in a
timely manner